LAVA Therapeutics NV (LVTX)
2.67
-0.09
(-3.26%)
USD |
NASDAQ |
May 17, 16:00
2.67
0.00 (0.00%)
After-Hours: 20:00
LAVA Therapeutics Shareholders Equity (Quarterly): 51.18M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 51.18M |
| September 30, 2023 | 54.60M |
| June 30, 2023 | 63.89M |
| March 31, 2023 | 75.28M |
| December 31, 2022 | 86.04M |
| September 30, 2022 | 92.66M |
| June 30, 2022 | 94.04M |
| Date | Value |
|---|---|
| March 31, 2022 | 108.41M |
| December 31, 2021 | 118.37M |
| September 30, 2021 | 128.50M |
| June 30, 2021 | 137.55M |
| March 31, 2021 | 133.02M |
| December 31, 2020 | 7.621M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
7.621M
Minimum
Dec 2020
137.55M
Maximum
Jun 2021
88.55M
Average
92.66M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| uniQure NV | 146.75M |
| ProQR Therapeutics NV | 37.60M |
| Merus NV | 349.45M |
| argenx SE | -- |
| Pharming Group | 205.94M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 101.71M |
| Total Liabilities (Quarterly) | 50.53M |
| Debt to Equity Ratio | 0.1032 |
| Current Ratio | 6.619 |
| Net Debt Paydown Yield | -0.53% |